There are 3 main clinical presentations of BrS: (1) polymorphic ventricular tachycardia (VT)/ventricular fibrillation (VF) associated with cardiac arrest (CA) or less frequently monomorphic VT 10 ; (2) syncope; and (3) no symptoms.
M ore than 20 years ago, the Brugada brothers reported 8 patients with recurrent episodes of aborted sudden death and no demonstrable heart disease having a peculiar ECG pattern of ST elevation in right precordial leads. 1 The Brugada syndrome (BrS), one of the most devastating causes of sudden cardiac death (SCD) in relatively young patients with apparently normal heart, was born. In fact, it is likely that the first case of BrS was reported a few years before by Martini et al. 2 The syndrome was recognized although not fully characterized even earlier in various southeastern Asian countries as responsible for mysterious cases of unexpected nocturnal SCD. 3 Over the following 2 decades, extensive research on the clinical and ECG aspects, electrophysiological (EP) mechanism, genetic background, and management of the syndrome has been accomplished. Two consensus reports on the diagnostic criteria, risk stratification, and management of BrS were published in 2005 4 and 2013. 5 Recent publication of several works dealing with various modes of management of BrS has raised questions about the optimal treatment that should be offered to these patients. Hereunder, I review these updated results and give my own viewpoint on the issue of management of BrS.
See Response by Sieira and Brugada

General Considerations
Importance of ECG Phenotype Ascertainment
Although there has been general initial consensus about the ECG definition of Brugada ECG pattern into 3 types (type 1, type 2, and type 3), 4 there has been a recent effort to establish a more simplified mode of classification, including only 2 ECG patterns 6 : pattern 1 identical to the classic type 1 of other consensus (coved pattern) and pattern 2 that joins patterns 2 and 3 of previous consensus (saddle-back pattern). This is in agreement with the classification presently adopted by most specialists that differentiates Brugada ECG type 1 versus nontype 1 patterns.
However, to date, only the ECG type 1 pattern (J-point elevation of ≥2 mm with a coved ST segment), spontaneously evident or induced by a provocative drug challenge, should be considered as the sine qua non-BrS diagnosis. [4] [5] [6] The other types are not considered diagnostic. In addition, it is of paramount importance to exclude various medical conditions, normal ECG variants, or ECG lead misplacement that can mimic Brugada ECG patterns [6] [7] [8] to avoid unnecessary implantable cardiac defibrillator (ICD) implantations. 8 We should recognize, however, that this is not always an easy task even for experienced specialists in the field. 9 
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Alternatives to ICD Therapy for Brugada Syndrome the BrS population. 12 Therefore, some workers included their patients with neurocardiogenic syncope in the asymptomatic group. 13 However, others 14 included them in the syncope group. In the FINGER registry (the France, Italy, Netherlands, Germany Brugada syndrome registry), 15 the word neurocardiogenic syncope did not appear in the article, but one might understand from the given definition of syncope (only that which has a probable arrhythmic origin) that neurocardiogenic syncope was included in the asymptomatic group. Finally, in PRElUDE (Programmed Electrical Stimulation Predictive Value registry), 16 the definition of the syncope group did not clearly indicate that patients with neurocardiogenic syncope were actually included in the asymptomatic group. The issue of the classification of patients with neurocardiogenic syncope is far to be semantical for 4 reasons: (1) increases in vagal tone may facilitate the onset of spontaneous VF in some BrS patients 17 ; (2) clinical symptoms suggesting of vagal syncope may be observed in syncope of cardiac origin 18 ; (3) an a priori inclusion of patients with neurocardiogenic syncope in the asymptomatic group may increase the threshold for not treating them; and (4) conversely an a priori inclusion of these patients in the syncope group may increase the threshold to treat them more aggressively (ICD, drugs, ablation). Therefore, and notwithstanding the great difficulties in establishing the actual cause of syncope in some patients, it is important and more scientifically correct that future studies clearly separate the suspected arrhythmic syncope from the neurocardiogenic type. 19
Arrhythmic Risk Stratification
The arrhythmic risk stratification of BrS has been the subject of many studies. The topic has been extensively reviewed by Adler et al. 20 An important pooled analysis of programmed ventricular stimulation (PVS) for risk stratification has been recently reported by Sroubek et al. 21 • Clinical parameters: the risk of arrhythmic event (AE) during follow-up is highest for patients presenting with CA, intermediate for patients with syncope, and lowest for patients who are asymptomatic when diagnosed.
• Age, sex, and genetics: although the prevalence of gene carriers among males and females is similar (BrS is an autosomal dominant genetic disorder with incomplete penetrance), the majority of diagnosed patients are male. First AEs usually occur between 35 and 55 years and very rarely in children or the elderly. SCN5A mutations are found in ≈30% of BrS patients. large registries have not found an association between the risk of VF and a family history of SCD or mutations in the SCN5A gene.
• ECG parameters: A spontaneous type 1 Brugada
ECG is an independent predictor of VF. In the largest multicenter study, 15 annual incidences of AE in asymptomatic patients with spontaneous and druginduced type 1 ECG were 0.8% and 0.4%, respectively, during a mean follow-up period of 31 months.
In the largest single-center study, 22 the figures were 1.2% and 0.3%, respectively, during a mean followup period of 73 months. The presence of early repolarization in peripheral leads, fragmented QRS complexes, late potentials, microscopic T wave alternans, and wide or large S wave in lead I have also shown promising results for predicting arrhythmic risk. 20, 23 • Value of PVS: Following the initial results of the Brugada group showing high value of PVS in predicting arrhythmic risk in BrS patients, 24 subsequent several large studies, including FINGER, 15 PRElUDE, 16 and 2 meta-analysis 25, 26 failed to confirm these results, leading to the abandon of PVS for risk stratification by many cardiac electrophysiologists. It is only recently, after the latest meta-analysis by Fauchier et al 27 and mostly the publication of the 20-year experience of the Pedro Brugada group in 404 patients with various clinical presentations of BrS, 13 that the beneficial role of PVS in arrhythmic risk stratification has been rehabilitated. In that study, VF inducibility presented a hazard ratio for AE of 8.3 (95% confidence interval 3.6-19.4), P<0.01. More importantly, the analysis by Sroubek et al 21 pooling the results of 8 studies (including FINGER 15 and PRElUDE 16 but not those of the Pedro Brugada group) concluded on the positive role of PVS in predicting future arrhythmic risk in BrS patients without a history of CA. This analysis showed that arrhythmia induction during PVS was associated with a 2.7-fold increased risk of AE over a median follow-up of 38 months. The risk was greatest among individuals who had their arrhythmias induced with single or double extrastimuli.
Latest Consensus Statement
In addition to lifestyle changes (avoidance of drugs that may induce or aggravate ST-segment elevation in right precordial leads, avoidance of excessive alcohol intake, immediate treatment of fever with antipyretic drugs), these guidelines recommend the following 5 
Presently Available Modalities of Treatment
There are presently 5 modalities of treatment of BrS patients:
(1) no treatment; (2) ICD implantation; (3) EP-guided class 1A antiarrhythmic therapy (mainly quinidine); (4) empirical quinidine therapy; and (5) epicardial ablation. As stated earlier, these modalities of treatment only concern the patients with the Brugada ECG type 1 (spontaneous or drug-induced). We will not deal here with the issue of the management of arrhythmic storms.
No Treatment
Some investigators 28 do not recommend any investigation (pharmacological testing or EP testing) for arrhythmic risk stratification in asymptomatic patients considered to be at low arrhythmic risk, such as those with no spontaneous ECG type 1 Brugada. Such decision may mainly affect female patients who have a lower incidence of spontaneous type 1 ECG. 29 However, in addition to the fact that pharmacological tests are mandatory for BrS diagnosis in patients with no spontaneous type 1 ECG, such a policy should take in account the following important points: (1) there is a strong day-to-day variability in the ECG diagnosis of Brugada type 1, as it was observed in a high-risk population with implanted ICD and spontaneous type 1 ECG, with only every third ECG being diagnostic and every third normal 30 ; (2) although the risk of AE is low in patients with no spontaneous type 1 Brugada ECG as compared with patients with spontaneous type 1, it is far from nil (annual rates of 0.4% and 0.3% in FINGER 15 and Sieira et al's study, 22 respectively); (3) although the proportion of female BrS patients with aborted CA was relatively low in FINGER 15 (11%) and in our experience 19 (10%), higher figures have been reported by the Pedro Brugada group (36%). 31 In this regard, it is noteworthy that women constituted 45% of the entire population of asymptomatic patients in the Pedro Brugada experience, 22 possibly because of exhaustive familial screening program established in their institution. Such sex distribution is more consistent with the autosomal mode of transmission of the disease. Moreover, in contrast to men, most women with BrS and resuscitated SCD or appropriate ICD shock do not have a spontaneous type 1 ECG pattern. 32 The nontherapy option also has been recommended in asymptomatic patients who underwent EP testing that yields no inducible arrhythmias. Such option can rely on the relatively low incidence rate of AE (3/289=1.04%, all patients without a spontaneous type 1 Brugada ECG, ie, only druginduced) found in these cases by Sieira et al 22 (Table 1) .
However, comparison between these 2 studies should be made with caution because of the marked higher proportion of patients with spontaneous type 1 ECG in Sroubek et al's analysis (≈50% versus 8.7%).
In our experience, no AE occurred during long period of follow-up (86.8±52 months) in any of our asymptomatic patients with no inducible arrhythmias. 19 This high negative predictive value of EP testing was obtained using an aggressive PVS protocol 19 only used in our laboratory. However, we should have in mind that BrS is a disease that may aggravate over the time, thus, requiring long periods of follow-up before the good long-term prognosis of patients with negative EP testing could be ascertained.
ICD Therapy
For the last 2 decades, ICD therapy has been considered as the cornerstone therapy of patients with documented ventricular tachyarrhythmias, as well as those assumed to be at high arrhythmic risk. The goal of ICD is to detect and treat any life-threatening tachyarrhythmias but not to prevent them. The only randomized trial showing a benefit of ICD in BrS has been DEBUT 33 (Defibrillator Versus β-Blockers for Unexplained Death in Thailand). The large experience with ICD accumulated during the last 20 years has been obtained with transvenous ICDs that were introduced almost at the same period of the princeps publication of the Brugada brothers. 1 Most recent techniques presently under evaluation involve subcutaneous electrode (S-ICD) and are expected to significantly reduce the rate of complications related to traditional transvenous ICD. Therefore, they might represent the most reasonable choice in the future for BrS patients who usually are young with an active lifestyle and long life expectancy.
Two studies including large cohorts (n=378 34 and n=176 31 ) of BrS patients implanted with transvenous ICDs with a followup of ≤20 years have been reported. Most patients included in these 2 studies had syncope (48%-60%), while only a minority (8%-14%) were CA survivors. ICD was found to be extremely effective in terminating arrhythmic episodes with only a single lethal case of refractory VF at 18 years of age in the first patient with BrS who presented to Pedro Brugada at 3 years of age. 35 However, transvenous ICD therapy has been associated with a significant rate of complications, including mainly (1) pocket/ leads infections because of multiple ICD replacements, device/ leads malfunction, or dislodgment; (2) inappropriate shocks mainly because of T wave oversensing and less commonly to noise related to myopotentials; and (3) psychological disorders. Finally, a few cases of near fatal AE have been reported in BrS patients wearing ICD, mainly in relation with arrhythmic storms, 36, 37 and should question the appropriateness of therapy using ICD alone in this group of patients.
EP-Guided Antiarrhythmic Therapy With Class 1A Antiarrhythmic Drugs
In contrast to ICD, this mode of therapy aims to prevent the arrhythmias rather than terminate them after they occur. Only
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Alternatives to ICD Therapy for Brugada Syndrome few laboratories worldwide have gained extensive experience with this mode of treatment. 19, 38 Among the class 1A drugs, procainamide is contraindicated because of its effect to unmask the BrS and induce arrhythmogenesis like class 1C drugs (flecainide and ajmaline). 39 We have recently reported our 33-year experience in 96 patients with various clinical presentations of BrS, including 3 patients studied before the initial publication of the Brugada brothers. 19 We found that quinidine (and disopyramide in some patients) was highly and similarly effective in preventing VF reinduction (≈90% efficacy) in CA survivors, as well as in those presenting with syncope or were asymptomatic. This result was achieved despite the use of an aggressive PVS protocol. No AE occurred during class 1A drug therapy in any of the EP drug responders during long follow-up periods. None of our 10 CA survivors treated with quinidine (including 9 EP-quinidine responders) experienced an AE during 146.4±90.9 months. This included our 3 patients who presented with arrhythmic storms and did not exhibit recurrent AE on medication during ≥22 years of follow-up. The latter patient even accepted not to have his ICD replaced on battery depletion. AE occurred in only 2 of our study patients who were CA survivors treated with ICD alone, but the arrhythmia did not recur during quinidine therapy in any of them. In patients who suffered recurrent syncope on quinidine, the mechanism of the syncope was clearly attributed to a nonarrhythmic mechanism (mainly vagal syncope). It is noteworthy that our 30 non-CA patients with no inducible arrhythmias at baseline remained arrhythmia-free on no therapy during long-term follow-up (129.9±27 months and 86.8±52 months in the syncope and the asymptomatic groups, respectively). Finally, our management policy enabled us to implant ICD in only 21% of the study patients, which is less than the implantation rate in other studies involving similar patient populations. In an earlier study, 40 we showed that the long-term reproducibility of the EP efficacy of quinidine in 5 patients with BrS was excellent, confirming that this therapeutic approach is a valuable long-term alternative to ICD therapy. However, this mode of therapy has 2 main adverse effects: (1) it resulted in 38% incidence of clinical side effects that were albeit transient but almost always required drug discontinuation 19 ; however, no instance of excessive QT prolongation has been observed in any of our patients; (2) a non-negligible proportion of patients who exhibited long-term poor compliance to their medications refused an ICD at this time. 19 In addition, quinidine was shown to be unavailable in many countries around the world, which prevents its wide use. 41 
Empirical Quinidine Therapy
Based on the experience gained with empirical drug therapy with β-blockers in the management of long QT syndrome and the great efficacy of quinidine in the management of BrS patients observed in our institution, Viskin et al 42 initiated in 2009 a prospective registry of empirical quinidine for asymptomatic BrS. Preliminary results in a small patient population are encouraging. 43 Such therapeutic approach, however, faces 3 main issues: (1) that of drug tolerance/compliance (as for the EP-guided quinidine therapy approach) 19 ; (2) it results in unnecessary management of a substantial number of patients at low to nil risk for AE; and (3) only long follow-up observation in a large patient cohort will be necessary before reaching any conclusion about such therapeutic option.
Ablation
Endocardial Ablation
In 2003, Haïssaguerre et al 44 were the first to report ablation of ventricular ectopy originating from the right ventricular outflow tract (RVOT) and the right ventricular anterior Purkinje system in 3 patients. Nakagawa et al 45 reported successful ablation of ventricular focus initiating arrhythmic storms in the posterolateral RVOT area. The RVOT location of most arrhythmias associated with BrS was corroborated by Morita et al. 46 In 4 patients with VF storms, Sunsaneewitayakul et al 47 from Thailand reported that endocardial catheter ablation of the late activation zone modified the Brugada ECG pattern in 3 and suppressed VF storm in all their patients during 12 to 30 months follow-up.
Epicardial Ablation
In 2011, Nademanee et al 48 from Thailand were the first to report on epicardial ablation in 9 patients with type 1 Brugada and a monthly median of 4 VT episodes requiring ICD shocks. Combined endocardial and epicardial mapping of the right ventricle revealed areas of abnormal low voltage with prolonged duration and fractionated electrograms localized to the anterior aspect of the RVOT epicardium. Ablation of these sites rendered VT/VF noninducible in 7/9 (78%) patients with no clinical recurrence during a mean follow-up of 20 months. The ECG pattern normalized after ablation in 8/9 (89%) patients. This study supports the hypothesis that abnormal delayed depolarization is the mechanism of VT/VF in BrS with an arrhythmogenic substrate localized to the RVOT epicardial region. Nademanee recently updated 49 The numbers in parentheses represent ranges.
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Alternatives to ICD Therapy for Brugada Syndrome arrhythmias). Interestingly, the arrhythmic substrate ablated was delineated by a flecainide infusion. After epicardial ablation, all patients became noninducible with PVS, and ECG did not show any change, suggesting BrS ECG pattern after flecainide infusion. After a median follow-up of 5 months, the ECG remained normal in all patients, despite flecainide testing, and ICD did not show any AE. Although significant complications were not reported during epicardial ablation of BrS in the 2 above mentioned studies, it is important to bear in mind that such a procedure may result in rare but severe complications. 51
Personal Viewpoint
Management of Cardiac Arrest Survivors
Although the guidelines recommend ICD therapy, our own experience suggests that EP-guided therapy with quinidine (or alternatively disopyramide) could be an excellent alternative to ICD if several conditions are fulfilled 19 : (1) sustained polymorphic ventricular tachycardia/VF is induced during EP testing; (2) the medication prevents arrhythmia reinduction during EP testing; (3) the medication is well tolerated during long term; and (4) patients are willing to accept the constraints of long-term antiarrhythmic medication and are aware of the necessity to undergo periodic EP testing (ie, every 5-10 years) to confirm persistence of noninducibility of VF over time (Figure 1 ).
An important prerequisite for a wide application of such a policy is the use of an aggressive PVS protocol 19 that both enables the achievement of highest sensitivity rates at baseline and optimizes the confidence in the response to medication when the arrhythmia is rendered no longer inducible. This aggressive protocol is in fact a modified conventional protocol (≤3 extrastimuli, 2 right ventricular sites, 2 basic cycle lengths) in which (1) pacing is performed using stimulus current of 2-to 5-fold the diastolic threshold and (2) double and triple extrastimulation are repeated 10× and 5×, respectively, at the shortest coupling intervals. It is noteworthy that using this protocol, we induced VF in all our CA survivors patients 19 (100% inducibility rate). In comparison, in the same patient population, an inducibility rate of 72% was achieved with conventional PVS protocols, 27 while an even lower rate (23.5%) was obtained by the Pedro Brugada group 13 with a protocol that is the least aggressive in the EP assessment of BrS (single right ventricular apical site, limitation of coupling intervals to ≥200 ms, no repetition of extrastimulation).
young patients and those who refuse the ICD therapy option or desire to postpone it may represent the best candidates. Decision on such policy should be taken after careful assessment of the patient's psychological profile, especially regarding the future compliance to long-term drug therapy.
An important advantage of EP-guided quinidine therapy over ICD therapy in CA survivors deals with the 40% 19 to 56% 31 of patients who remain arrhythmia-free during long-term follow-up but are, nonetheless, committed to have their ICD replaced on battery depletion. In this respect, 2 studies 52, 53 showed that the arrhythmic risk recurrence markedly decreased with age. I think that long-term well-tolerated quinidine therapy (ie, 2-3 daily tablets of 300 mg hydroquinidine) would be better accepted by these patients than multiple ICD replacements with their inherent risk of complications. Successful long-term management of arrhythmic storms with quinidine during ≤40 years have been reported in 2 patients with idiopathic VF, 54,55 including 1 of our patients 55 who is presently enjoying his 37th year without ICD.
Of course, an ICD is recommended for patients who have persistent VF inducibility on quinidine or who develop drug intolerance or become noncompliant with medications.
Management of Patients With Syncope Suspected to Have an Arrhythmic Origin
This group of patients represents probably the one which needs the most careful clinical assessment. Although there is consensual agreement that most cases of syncope in BrS patients have a nonarrhythmic mechanism, 19,56 some may be related to a paroxysmal malignant ventricular arrhythmia (Figure 1) . A systematic history taking looking mainly for presence/ absence of prodromes and specific triggers has been shown to be useful in distinguishing arrhythmic from nonarrhythmic syncope. 12 Male sex and older age at time of first syncope also have been shown to suggest an arrhythmic origin. 12 For those BrS patients with syncope suspected to have an arrhythmic origin, I think there are 2 therapeutic options: (1) ICD therapy (as recommended by the guidelines); and (2) EP testing using our aggressive PVS protocol as used for CA survivors (see above). The inability to induce VF at baseline will allow recommending no therapy. EP-guided quinidine therapy enables avoidance of an ICD in a non-negligible proportion of patients. 
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Management of Asymptomatic Patients (Including Patients With Neurocardiogenic Syncope)
This group of patients represents the largest BrS patient population encountered worldwide and certainly the one that is the most difficult to manage ( Figure 2 ). like Pedro Brugada, I do recommend EP testing for arrhythmic stratification in these patients. Nonetheless, I do not recommend using our aggressive PVS protocol for this purpose because it has shown an unacceptable high inducibility rate (61%) in this patient group. 19 Taking in account the fact that the PVS protocol used by the Pedro Brugada group 13 achieved the highest positive predictive value (18.2%) and negative predictive value (98.3%) ever reported in asymptomatic patients, I have suggested using their PVS protocol 57 with adjustment of the stimulus current intensity to 2 to 5 the diastolic threshold instead of their fixed 4 mA and inclusion of repetition of double extrastimulation (n=10) and triple extrastimulation (n=5) at the shortest coupling intervals (≥200 ms). The latter modifications aim to further increase protocol sensitivity. Patients with inducible VF will be invited to undergo EP-guided quinidine testing. ICD will be recommended in case of persistent VF inducibility on medication, drug-induced side effects, or poor patient compliance to medications. Patients with no inducible arrhythmias will be followed on no therapy.
What Should Be the Place of Epicardial Ablation?
For CA survivors with implanted ICD who have recurrent AE, epicardial ablation certainly represents a promising therapeutic option. It is noteworthy, however, that the promoters of this mode of therapy are presently reluctant to leave their patients without back-up ICD even if the ECG Brugada pattern and the VF inducibility are abolished. The fact that Nademanee 49 recently reported persistent VF inducibility in ≈40% of patients after successful epicardial ablation casts a doubt about any change of their policy in the future. Thus, it seems that epicardial ablation will presently serve as an adjuvant rather than an alternative to ICD therapy in patients with recurrent AE.
The question whether epicardial ablation should be proposed to other groups of patients considered at increased arrhythmic risk with the aim to avoid ICD or drug therapy will deserve further studies. In the patient reported by Széplaki et al 58 (a 31-year-old male with syncope, spontaneous type 1 Brugada ECG and negative EP testing who refused the implantation of an ICD), epicardial ablation was offered and successfully performed. I assume that such a policy will gain popularity in the future in centers that have great expertise in the field of epicardial ablation.
Conclusions
From the experience accumulated to date, it seems that ICDs no longer warrant the quote that they are the "only therapy with proven efficacy for the management of patients with BrS". I think it would be more appropriate to state that there are presently several possible modes of management of the BrS, each of them presenting advantages and disadvantages. A multicenter study performed in institutions where all modes of therapy are available is certainly warranted, but I guess that most research efforts will focus on comparison of ICD therapy and epicardial ablation. 49 Meanwhile, it is important to objectively inform the patient about these various modalities of treatment. Patient's final decision is likely to be affected by the cardiac electrophysiologist's experience and personal preference for each of these therapeutic options, as well as the availability of pericardial interventions or quinidine in the physician's institution. At this stage, my impression is that epicardial ablation might play an increasing role in the future because the number of cardiac electrophysiologists gaining experience in epicardial ablation of ventricular tachyarrhythmias is growing. A major breakthrough will certainly be achieved when the epicardial ablation option will render the need for ICD implantation obsolete. It is likely that the Brugada brothers, at the time they reported their malignant electric syndrome, could not have believed that it will be managed <2 decades later by epicardial ablation of the RVOT using a technique developed by eminent Thai cardiac electrophysiologists. Dr Belhassen presents an electrophysiological-guided approach for the management of Brugada syndrome patients. This is a very valuable strategy that might reduce the number of implantable cardioverter defibrillator implantations and, what is even more interesting, the number of arrhythmic events in this population. Nevertheless, we have several concerns. We have presented our doubts about the long-term efficacy of quinidine in preventing arrhythmic events, especially in real-life settings. We believe that the drug, as opposed to implantable cardioverter defibrillator implantation, cannot guarantee complete protection of all patients. Pathophysiological mechanisms underlying Brugada syndrome are diverse, and the drug might not act on all of them. 1 Furthermore, secondary effects of the drug are relevant and limit its use. 2 Electrophysiological-guided therapy for high-risk patients, survivors of a sudden cardiac death or even those with syncope, have excellent outcomes in highly experienced hands. 2 Generalization and adoption by less experienced physicians might jeopardize the patients' prognosis. As Dr Belhassen points out, several requisites have to be fulfilled to adopt this strategy, which include a careful selection of patients and their awareness of the necessity of high therapeutic compliance. Drug compliance in other fields of cardiology is far from perfect, 3 and in Brugada syndrome, its lack might mean the death of the patient. Compliance of asymptomatic patients taking a drug with a prophylactic intention that has multiple side effects has to be carefully assessed before recommending its generalization.
Asymptomatic patients, especially those with a nonspontaneous drug-induced ECG type 1 pattern, merit special consideration. They are probably the most numerous group, and their management is challenging and even controversial. 4 We have always supported the value of electrophysiological study in the risk stratification of these patients. A mild stimulation protocol achieves a very high negative predictive value, but arrhythmic events can still happen. We believe that other characteristics have also to be considered (such as spontaneous type 1 pattern, familial antecedents, ECG characteristics, etc). The electrophysiological-based strategy proposed by Dr Belhassen, with a mild stimulation protocol, has undoubtedly great advantages, but it needs the support of further evidence.
Up to this time, we believe that implantable cardioverter defibrillator placement is the only strategy that fully protects Brugada syndrome patients. Its protection is reproducible and not limited by the physician's experience or patients' behavior. We believe that risk stratification is of utmost importance to adequately identify those patients who will benefit from it. A drug-based strategy that effectively eliminates arrhythmic events, that is well tolerated, and that achieves high compliance is desirable. Quinidine does not meet these goals. However, we believe that the protocol presented by Dr Belhassen is highly valuable, with excellent outcomes, and could constitute an alternative to an implantable cardioverter defibrillator in selected patients.
